1- And 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans

Drug Metabolism and Disposition

Volumn 26, Issue 11, 1998, Pages 1096-1101

  Eiermann, Birgit ^b   Edlund, Per Olof ^b   Tjernberg, Agneta ^b   Dalén, Per ^b   Dahl, Marja Liisa ^b   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE;

ARTICLE; CATALYSIS; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SCREENING; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CANIS FAMILIARIS;

EID: 0031739606     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodriguez F and Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446.
2. Allen JG, Brown AN and Marten TR (1976) Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica 6:405-409.
3. Allen JG, East PB, Francis RJ and Haigh JL (1975) Metabolism of debrisoquine sulfate: identification of some urinary metabolites in rat and man. Drug Metab Dispos 3:332-337.
4. Alvan G, Bechtel P, Iselius L, and Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537.
5. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TJ, Liao XM, Wang KY, Reviviego J, Iselius L and Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
6. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M and Sjöqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520.
7. Eichelbaum M, Bertilsson L, Küpfer A, Steiner E and Meese CO (1988) Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmacol 25:505-508.
8. Eichelbaum M and Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 46:377-394.
9. Eichelbaum M, Spannbrucker N, Steinke B and Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187.
10. Evans DA, Mahgoub A, Sloan TP, Idle JR and Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17:102-105.
11. 14C]-debrisoquine in man. Br J Clin Pharmacol 7:257-266.
12. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F and Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829.
13. Koymans LMH, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W and Donné-Opdenkelder GM (1992) A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
14. Mahgoub A, Idle JR, Dring LG, Lancaster R and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
15. Strobl GR, von Kreudener S, Stöckigt J, Guengerich FP and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. J Med Chem 36:1136-1145.